Peter Lynch fit · Growth at a reasonable price (GARP)
Is Gyre Therapeutics, Inc. Common Stock (GYRE) a Peter Lynch Stock?
Does not fit Lynch's GARP criteria — growth too low or price too high.
7/100
FPas un fit
2/6 critères validés
Les critères de Peter Lynch, appliqués à GYRE
PEG ≤ 1.0
clé—
EPS CAGR ≥ 15%
clé0.0%
Revenue CAGR ≥ 10%
-13.2%
Net margin > 0
6.2%
Comment GYRE se classe selon d'autres stratégies
Données financières en direct
Cap. boursière
$731.67M
PER (TTM)
55.7x
ROIC (TTM)
11.69%
Marge brute
95.48%
Questions fréquentes
What is GYRE's Peter Lynch fit score?
GYRE scores 7/100 on our Peter Lynch fit engine — grade F. Does not fit Lynch's GARP criteria — growth too low or price too high.
Does Peter Lynch actually own GYRE?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends GYRE.
How often is this score updated?
GYRE's Peter Lynch fit score is recomputed daily from the latest TTM financials.
Outil éducatif, pas un conseil en investissement. Les scores sont calculés à partir de données financières publiques selon les critères publiés de chaque stratégie d'investissement. Nous ne prétendons pas que Peter Lynch possède ou recommande GYRE personnellement.